News about Cathie Wood

Ark Invest founder Cathie Wood holds $379.1 million of CRISPR Therapeutics shares and bought $1.1 million on Oct. 9 and $2.3 million on Oct. 12 through the ARK Genomic Revolution ETF, even though the stock is down more than 25% over the past year. CRISPR's only approved therapy, Casgevy, posted $76 million in Q2 revenue, up 151% year over year, but its $2.2 million list price and the 60% revenue share going to Vertex limit its economics. The company's net loss narrowed to $91.2 million from $208.5 million, and it holds $2.36 billion in cash. The article also points to CTX-310, which cut LDL cholesterol by 53% and triglycerides by 48% after 12 months in a phase 1a trial, and to a phase 2 readout for blood thinner CTX611 expected later this year.